SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Nived Ola) ;mspu:(researchreview)"

Sökning: WFRF:(Nived Ola) > Forskningsöversikt

  • Resultat 1-3 av 3
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Jönsen, Andreas, et al. (författare)
  • Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts
  • 2016
  • Ingår i: Seminars in Arthritis & Rheumatism. - : Elsevier BV. - 0049-0172 .- 1532-866X. ; 45:6, s. 684-690
  • Forskningsöversikt (refereegranskat)abstract
    • Objectives: The main objectives of this study were to calculate total costs of illness and cost -driving disease features among patients with systemic lupus erythematosus (SLE) in Sweden. Methods: Five cohorts of well-defined SLE patients, located in different parts of the country were merged. Incident and prevalent cases from 2003 through 2010 were included. The American College of Rheumatology (ACR) classification criteria was used. From the local cohorts, data on demographics, disease activity (SLEDAI 2K), and organ damage (SDI) were collected. Costs for inpatient care, specialist outpatient care and drugs were retrieved from national registries at the National Board of Health and Welfare. Indirect costs were calculated based on sickness leave and disability pensions from the Swedish Social Insurance Agency. Results: In total, 1029 SLE patients, 88% females, were included, and approximately 75% were below 65 years at the end of follow-up, and thus in working age. The mean number of annual specialist physician visits varied from six to seven; mean annual inpatient days were 3.1-3.6, and mean annual sick leave was 123-148 days, all per patient. The total annual cost was 208,555 SEK ($33,369 = 22,941(sic)), of which direct cost was 63,672kr ($10,188 = 7004(sic)) and the indirect cost was 144,883 SEK ($23,181 = 15,937(sic)), all per patient. The costs for patients with short disease duration were higher. Higher disease activity as measured by a SLEDAI 2K score > 3 was associated with approximately 50% increase in both indirect and direct costs. Damage in the neuropsychiatric and musculoskeletal domains were also linked to higher direct and indirect costs, while organ damage in the renal and ocular systems increased direct costs. Conclusion: Based on this study and an estimate of slightly more than 6000 SLE patients in Sweden, the total annual cost for SLE in the country is estimated at $188 million (= 129.5 million (sic)). Both direct (30%) and indirect costs (70%) are substantial. Medication accounts for less than 10% of the total cost. The tax paid national systems for health care and social security in Sweden ensure equal access to health care, sick leave reimbursements, and disability pensions nationwide. Our extrapolated annual costs for SLE in Sweden are therefore the best supported estimations thus far, and they clearly underline the importance of improved management, especially to reduce the indirect costs. (C) 2016 Elsevier Inc. All rights reserved.
  •  
2.
  • Mikdashi, Jamal, et al. (författare)
  • Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research.
  • 2015
  • Ingår i: Arthritis Research and Therapy. - : Springer Science and Business Media LLC. - 1478-6362 .- 1478-6354. ; 17
  • Forskningsöversikt (refereegranskat)abstract
    • Measuring lupus disease activity accurately remains a challenging and demanding task given the complex multi-system nature of lupus, an illness known for its variability between patients and within the same patient over time. Many have attempted to define what disease activity means and how it should be measured, and several instruments were devised for a standardized assessment of disease activity and outcome domains in clinical research. Several of these measuring tools have been able to detect clinical improvement and have demonstrated adequate reliability, validity, and sensitivity to change in observational studies, and some were found to be useful in randomized controlled trials. However, several failed clinical trials have confronted these metrics, as they were not intended for clinical trials. The Outcome Measures Rheumatology group and the US Food and Drug Administration have recommended using measures of disease activity, cumulative organ damage, health-related quality of life, and adverse events as outcomes of interest. Composite responder indices that determine disease global improvement, ensure no significant worsening in unaffected organ systems, and include a physician's global assessment have been used in randomized clinical trials. Yet unmet therapeutic needs were further challenged by the complex content and psychometric information of the updated instruments, including increased administrative burden associated with demanding training and cost of instruments, and small effect size associated with responsiveness to patient concerns. Nevertheless, with the progress of novel targeted therapy, refining the disease activity metrics is essential. Selection of the disease activity endpoints which is a defining aspect of clinical trial design must be tailored to the outcome of interest and measured by a reliably rated scale characterized by minimal administrative burden. An optimal scale should be simple and practical and incorporate elements of patient concerns.
  •  
3.
  • Ryden-Aulin, Monica, et al. (författare)
  • Off-label use of rituximab for systemic lupus erythematosus in Europe
  • 2016
  • Ingår i: Lupus Science and Medicine. - : BMJ. - 2053-8790. ; 3:1
  • Forskningsöversikt (refereegranskat)abstract
    • Objectives: Rituximab (RTX) is a biological treatment used off-label in patients with systemic lupus erythematosus (SLE). This survey aimed to investigate the off-label use of RTX in Europe and compare the characteristics of patients receiving RTX with those receiving conventional therapy. Methods: Data on patients with SLE receiving RTX were taken from the International Registry for Biologics in SLE retrospective registry and complemented with data on patients with SLE treated with conventional therapy. For nationwide estimates of RTX use in patients with SLE, investigators were asked to provide data through case report forms (CRFs). Countries for which no data were submitted through CRFs, published literature and/or personal communication were used, and for European countries where no data were available, estimates were made on the assumption of similarities with neighbouring countries. Results: The estimated off-label use of RTX in Europe was 0.5%-1.5% of all patients with SLE. In comparison with patients with SLE on conventional therapy, patients treated with RTX had longer disease duration, higher disease activity and were more often treated with immunosuppressives. The most frequent organ manifestations for which either RTX or conventional therapy was initiated were lupus nephritis followed by musculoskeletal and haematological. The reason for treatment was, besides disease control, corticosteroid-sparing for patients treated with conventional therapy. Conclusions: RTX use for SLE in Europe is restrictive and appears to be used as a last resort in patients for whom other reasonable options have been exhausted.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-3 av 3
Typ av publikation
Typ av innehåll
refereegranskat (3)
Författare/redaktör
Nived, Ola (3)
Bengtsson, Anders (1)
Gunnarsson, Iva (1)
Svenungsson, Elisabe ... (1)
Jönsen, Andreas (1)
Rönnblom, Lars (1)
visa fler...
Sjöwall, Christopher (1)
Steen Carlsson, Kata ... (1)
van Vollenhoven, Ron ... (1)
Rantapää-Dahlqvist, ... (1)
Ruiz-Irastorza, Guil ... (1)
Isenberg, David (1)
Ramos-Casals, Manuel (1)
Inanc, Murat (1)
Willim, Minna (1)
Petersson, Ingemar (1)
Kovacs, Laszlo (1)
Zickert, Agneta (1)
Mariette, Xavier (1)
Bengtsson, Christine (1)
Jacobsen, Soren (1)
Pettersson, Susanne (1)
Doria, Andrea (1)
Rydén-Aulin, Monica (1)
Leonard, Dag (1)
Sáez-Comet, Luis (1)
Houssiau, Frédéric A ... (1)
Bultink, Irene (1)
Voskuyl, Alexandre (1)
Sebastiani, Gian Dom ... (1)
Gustafsson, Johanna ... (1)
Szücs, Gabriella (1)
Mosca, Marta (1)
Huizinga, Tom (1)
Dorner, Thomas (1)
Hjalte, Frida (1)
Mikdashi, Jamal (1)
Boumpas, Dimitrios (1)
Rubio, Jose Luis Cal ... (1)
Caminal-Montero, Lui ... (1)
Castro, Antoni (1)
Ruiz, Agustín Colodr ... (1)
Gonzalez-Echavarri, ... (1)
Gremese, Elisa (1)
Iuliano, Annamaria (1)
Jimenez-Alonso, Juan (1)
Oristrell, Joaquim (1)
Rascon, Javier (1)
Cervello, Gonzalo Sa ... (1)
Squatrito, Danilo (1)
visa färre...
Lärosäte
Lunds universitet (3)
Karolinska Institutet (2)
Umeå universitet (1)
Uppsala universitet (1)
Linköpings universitet (1)
Språk
Engelska (3)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (3)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy